Day: August 4, 2021

SAMPO PLC                HALF-YEAR FINANCIAL REPORT        4 August 2021 at 9:30 am Sampo Group’s results for January – June 2021         Sampo Group delivered strong performance across all its business units in January – June 2021. Profit before taxes grew to EUR 1,343 million (569) and earnings per share increased to EUR 1.80 (0.81). Sampo Group’s core business, P&C insurance, achieved an underwriting result of EUR 658 million (489) for the first half of 2021, representing year-on-year growth of 34 per cent. Adjusting for the Hastings acquisition and COVID-19 effects reported by If P&C and Topdanmark, underwriting profit growth was 12 per cent. The Group combined ratio improved by 1.9 percentage points year-on-year to 80.7 per cent (82.6). The strong result is well ahead of Sampo Group’s 2021–2023 annual financial targets...

The CEO of Martela Corporation, Artti Aurasmaa, has decided to step down from his role to take a new position in another organization. Aurasmaa will continue to work for Martela up to the end of his six-month notice period. The Board of Directors at Martela will immediately launch the search for a new CEO. “We have revised Martela’s strategy during the past year, and the operational team is extremely competent. The company has advanced to a vanguard position in modern hybrid work. Its delivery capability is in good shape as the pandemic eases out, and customer satisfaction is at an excellent level. In this situation, with a confident mind, I have decided to accept a new challenge outside Martela,” Artti Aurasmaa says. “I want to extend warm thanks to Artti for his contribution at Martela and wish him all the best to the next challenges....

The 130-wind turbine project strengthens Ørsted’s Texas asset base as it continues to scale the business. Ørsted has completed the 367 MW Western Trail Wind Farm located in Wilbarger and Baylor counties, Texas – its largest onshore wind project to date that brings Ørsted’s total onshore capacity to over 2.8 GW of wind, solar, and battery storage in operation. The project has secured long-term power purchase agreements with PepsiCo, Hormel Foods, and Nucor for the majority of the power generated from the project. Both PepsiCo and Hormel Foods will also purchase power from the Haystack Wind project in SPP (Southwest Power Pool), due online later this year. “Western Trail Wind is a well-sited greenfield development project that will provide low-cost, reliable power to the Texas grid,” said Philip Moore, Senior Vice President of Ørsted Onshore....

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinOther stakeholders 4 August 2021 Ringkjøbing Landbobank’s interim report for the first half of 2021 The bank delivers core earnings of DKK 727 million and profit before tax of DKK 716 million in the first half of 2021. The profit before tax is equivalent to a return on equity of 17.4% p.a. Core earnings(DKK million) H1 2021 H1 2020   2020 2019      2018        2017       Total core income 1,179 1,061 2,179 2,116 2,001 1,917Total expenses and depreciation 404 390 788 805 866 845Core earnings before impairment charges for loans 775 671 1,391 1,311 1,135 1,072Impairment charges for loans etc. -48 -141 -223 -100 -43 -70Core earnings 727 530 1,168 1,211 1,092 1,002Result for the portfolio etc. -3 -41 -9 +49 +77 +84Special costs 8 8 15 15 217 22Profit before...

 On target to grow the broad product pipeline with at least 3 additional programmes before end 2021Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month period ending 30 June 2021, a year-to-date business update, and an outlook for the remainder of the year. Stijn Van Rompay,...

August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in a fireside chat at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 11:30 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the call. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation...

4 August 2021 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 listing rules: GAM Holding AG announces first half 2021 results Financial highlightsGroup assets under management increased to CHF 126.0 billion1as at 30 June 2021 (compared with CHF 122.0 billion as at 31 December 2020)Underlying profit before tax of CHF 0.8 million in the first half of 2021 (compared with underlying loss of CHF 2.0 million in first half of 2020)IFRS net loss of CHF 2.7 million (compared with a net loss of CHF 390.1 million in first half of 2020) Investment management saw net client outflows of CHF 2.2 billion in the first half of 2021, with private labelling recording net client inflows of CHF 0.8 billion 74% of investment management assets under management outperformed their benchmark over five yearsStrategic progressDistribution footprint...

– A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction– –A Mechanism of Action Trial Assessing the Effect of Nolasiban on Contractions, Blood Flow and Gene Expression in the Uterus Published in the Journal of Reproductive BioMedicine Online–   Geneva, Switzerland and Boston, MA – August 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF). The first paper,...

Rotterdam, The Netherlands (4 August 2021) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of specialitychemicals and ingredients, today announces its first half year 2021 results. HIGHLIGHTS • Gross profit growth of 23% to EUR 410.9 million (+28% on a constant currency basis)• Operating EBITA increase of 46% to EUR 192.3 million (+52% on a constant currency basis)• Net result before amortisation and non-recurring items increase of 52% to EUR 137.5 million (+57% on a constantcurrency basis)• Cash earnings per share increased by 44% to EUR 2.43 (first half of 2020: EUR 1.69)• In the second quarter of 2021, IMCD completed the acquisitions of Siliconas in Colombia, Andes Chemical in theUS, Colombia and Peru and Yuanhe Chemicals in China Piet van der Slikke, CEO: “We are reporting very strong results...

Good progress and broad-based performance, delivered in a quality way PRESS RELEASE Amsterdam, 4 August 2021Key items1Total organic sales grew 4.2%, supported by In-Home momentum (+4.9%) and fuelled by Single Serve and Beans growing double-digit. E-commerce grew by 30% In-Home Away-from-Home returned to profitability, despite largely stable sales base on average for H1 (+0.7%) although with visible positive reopening effects in Q2 Organic adjusted EBIT grew 0.8% to EUR 636 million, with gross profit margin expansion Free cash flow of EUR 553 million and net debt reduced to EUR 4,660 million Leverage reduced to 2.98x, from 3.23x at the end of FY 20 Underlying EPS grew 12.9%, mainly supported by operational improvements Positive market share performance across technologies and continued progress on Sustainability Confident to reach FY...